DE69421624D1 - Medikamente bindendes protein - Google Patents

Medikamente bindendes protein

Info

Publication number
DE69421624D1
DE69421624D1 DE69421624T DE69421624T DE69421624D1 DE 69421624 D1 DE69421624 D1 DE 69421624D1 DE 69421624 T DE69421624 T DE 69421624T DE 69421624 T DE69421624 T DE 69421624T DE 69421624 D1 DE69421624 D1 DE 69421624D1
Authority
DE
Germany
Prior art keywords
binding protein
assays
relates
encoding same
medicine binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69421624T
Other languages
English (en)
Other versions
DE69421624T2 (de
Inventor
John C Lee
Jerry L Adams
Timothy F Gallagher
David W Green
John Richard Heys
Peter C Mcdonnell
Dean E Mcnulty
James E Strickler
Peter R Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
GlaxoSmithKline LLC
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/250,975 external-priority patent/US5783664A/en
Application filed by GlaxoSmithKline LLC, SmithKline Beecham Corp filed Critical GlaxoSmithKline LLC
Application granted granted Critical
Publication of DE69421624D1 publication Critical patent/DE69421624D1/de
Publication of DE69421624T2 publication Critical patent/DE69421624T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
DE69421624T 1993-09-17 1994-09-16 Medikamente bindendes protein Expired - Lifetime DE69421624T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12317593A 1993-09-17 1993-09-17
US08/250,975 US5783664A (en) 1993-09-17 1994-05-31 Cytokine suppressive anit-inflammatory drug binding proteins
PCT/US1994/010529 WO1995007922A1 (en) 1993-09-17 1994-09-16 Drug binding protein

Publications (2)

Publication Number Publication Date
DE69421624D1 true DE69421624D1 (de) 1999-12-16
DE69421624T2 DE69421624T2 (de) 2000-07-20

Family

ID=26821313

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69421624T Expired - Lifetime DE69421624T2 (de) 1993-09-17 1994-09-16 Medikamente bindendes protein

Country Status (15)

Country Link
US (3) US5871934A (de)
EP (1) EP0724588B1 (de)
JP (1) JP3377529B2 (de)
CN (1) CN1048731C (de)
AT (1) ATE186551T1 (de)
AU (1) AU686669B2 (de)
CA (1) CA2171982C (de)
DE (1) DE69421624T2 (de)
DK (1) DK0724588T3 (de)
ES (1) ES2140561T3 (de)
GR (1) GR3032635T3 (de)
HK (1) HK1012399A1 (de)
NZ (1) NZ274063A (de)
PT (1) PT724588E (de)
WO (1) WO1995007922A1 (de)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
ES2208698T3 (es) * 1994-12-13 2004-06-16 F. Hoffmann-La Roche Ag Derivados de imidazol.
ATE362380T1 (de) * 1995-03-31 2007-06-15 Xenova Res Ltd Hapten-träger-konjugate zur anwendung in der drogen-missbrauchs-therapie
DE69637846D1 (de) * 1995-12-06 2009-04-09 Dainippon Sumitomo Pharma Co Neues semaphorin z und dafür kodierendes gen
US6218136B1 (en) * 1996-03-12 2001-04-17 Smithkline Beecham Corporation Methods of the identification of pharmaceutically active compounds
EP0889887A4 (de) * 1996-03-25 2003-06-11 Smithkline Beecham Corp Behandlung von verletzungen des zentralen nervensystems
US6677130B1 (en) 1996-05-20 2004-01-13 Signal Pharmaceuticals, Inc. Mitogen-activated protein kinase p38-2 and methods of use therefor
US5948885A (en) 1996-05-20 1999-09-07 Signal Pharmaceuticals, Inc. Mitogen-activated protein kinase p38-2 and methods of use therefor
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
AU7966198A (en) 1997-06-13 1998-12-30 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds
JP2002505690A (ja) 1997-06-19 2002-02-19 スミスクライン・ビーチャム・コーポレイション 新規なアリールオキシピリミジン置換イミダゾール化合物
US6489325B1 (en) 1998-07-01 2002-12-03 Smithkline Beecham Corporation Substituted imidazole compounds
TW517055B (en) * 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
US7301021B2 (en) * 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6562832B1 (en) 1997-07-02 2003-05-13 Smithkline Beecham Corporation Substituted imidazole compounds
JP2001518507A (ja) 1997-10-08 2001-10-16 スミスクライン・ビーチャム・コーポレイション 新規シクロアルケニル置換化合物
CA2223075A1 (en) * 1997-12-02 1999-06-02 Smithkline Beecham Corporation Drug binding protein
JP2001526230A (ja) 1997-12-19 2001-12-18 スミスクライン・ビーチャム・コーポレイション ヘテロアリール置換イミダゾール化合物、その医薬組成物および使用
PT1043995E (pt) * 1997-12-22 2007-01-31 Bayer Pharmaceuticals Corp Inibição da actividade de p38-quinase utilização de ureias heterocíclicas substituídas com arilo ou heteroarilo
WO1999032111A1 (en) 1997-12-22 1999-07-01 Bayer Corporation INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
ATE266399T1 (de) * 1998-08-20 2004-05-15 Smithkline Beecham Corp Neue substituierte triazolverbindungen
US6268352B1 (en) * 1998-09-02 2001-07-31 The Regents Of The University Of California Promoters of neural regeneration
AU1909200A (en) 1998-11-04 2000-05-22 Smithkline Beecham Corporation Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
US20020065296A1 (en) 1999-01-13 2002-05-30 Bayer Corporation Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
IL144144A0 (en) 1999-01-13 2002-05-23 Bayer Ag Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
UA73492C2 (en) * 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
WO2000050425A1 (en) 1999-02-22 2000-08-31 Boehringer Ingelheim Pharmaceuticals, Inc. Polycyclo heterocyclic derivatives as antiinflammatory agents
CN1511830A (zh) 1999-03-12 2004-07-14 ���ָ��.Ӣ��ķҩ�﹫˾ 作为消炎剂的化合物
MXPA01009077A (es) 1999-03-12 2002-03-27 Boehringer Ingelheim Pharma Composiciones heterociclicos aromaticos como agentes anti-inflamatorios.
US6287773B1 (en) * 1999-05-19 2001-09-11 Hoeschst-Ariad Genomics Center Profile searching in nucleic acid sequences using the fast fourier transformation
ES2253233T3 (es) * 1999-07-09 2006-06-01 Boehringer Ingelheim Pharmaceuticals Inc. Procedimiento para sintesis de compuestos de urea heteroaril sustituidos.
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
JP2003528043A (ja) 1999-11-23 2003-09-24 スミスクライン・ビーチャム・コーポレイション ＣＳＢＰ／ｐ３８キナーゼ阻害剤としての３，４‐ジヒドロ−（１Ｈ）キナゾリン−２−オン化合物
EP1233951B1 (de) 1999-11-23 2005-06-01 SmithKline Beecham Corporation 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
US7053099B1 (en) 1999-11-23 2006-05-30 Smithkline Beecham Corporation 3,4-dihydro-(1H)quinazolin-2-one compounds as CSBP/p38 kinase inhibitors
US6525046B1 (en) 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
US6608052B2 (en) 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
US7235551B2 (en) * 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
JP2003535062A (ja) * 2000-06-01 2003-11-25 メルク エンド カムパニー インコーポレーテッド Ｊｎｋ阻害剤としての（二置換フェニル）ピリミジニルイミダゾール誘導体の使用
KR100850812B1 (ko) * 2000-10-23 2008-08-06 스미스클라인 비참 코포레이션 신규 화합물
WO2002063029A1 (en) * 2001-02-02 2002-08-15 Iconix Pharmaceuticals, Inc. Alteration of phenotype due to heterologous genes
BR0207957A (pt) 2001-03-09 2004-02-25 Pfizer Prod Inc Compostos antiinflamatórios de benzimidazol
OA12552A (en) 2001-03-09 2006-06-06 Pfizer Prod Inc Triazolopyridines as anti-inflammatory agents.
ES2247271T3 (es) 2001-04-04 2006-03-01 Pfizer Products Inc. Nuevos benzotriazoles como compuestos antiinflamatorios.
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
CA2465759A1 (en) * 2001-12-11 2003-06-19 Boehringer Ingelheim Pharmaceuticals, Inc. Method for administering birb 796 bs
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
JP4527401B2 (ja) 2002-02-11 2010-08-18 バイエル、ファーマシューテイカルズ、コーポレイション キナーゼ阻害剤としてのアリール尿素
JP4636486B2 (ja) 2002-02-11 2011-02-23 バイエル、ファーマシューテイカルズ、コーポレイション 脈管形成阻害活性を有するアリール尿素
WO2003072569A1 (en) * 2002-02-25 2003-09-04 Boehringer Ingelheim Pharmaceuticals, Inc. 1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
US20060105445A1 (en) * 2002-07-29 2006-05-18 Klaus Godl Medium and method for enriching, purifying or depleting atp binding proteins from a pool of proteins
US7037923B2 (en) * 2002-08-30 2006-05-02 Pfizer, Inc. Alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines
US6949652B2 (en) * 2002-08-30 2005-09-27 Pfizer, Inc. Crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-A]pyridine
PA8579601A1 (es) * 2002-08-30 2004-05-07 Pfizer Prod Inc Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas
US20040092547A1 (en) * 2002-08-30 2004-05-13 Pfizer Inc Alkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
US7012143B2 (en) 2002-08-30 2006-03-14 Dombroski Mark A Cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
US7005523B2 (en) * 2002-08-30 2006-02-28 Pfizer Inc. Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines
US6803748B2 (en) * 2003-02-03 2004-10-12 Delphi Technologies, Inc. System and method for controlling load dump voltage of a synchronous machine
US7557129B2 (en) * 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
MXPA05012377A (es) * 2003-05-15 2006-05-25 Arqule Inc Derivados de imidazotiazoles e imidazoxazol como inhibidores de p38.
ES2305808T3 (es) 2003-05-20 2008-11-01 Bayer Healthcare Llc Diarilureas con actividad inhibidora de quinasas.
CL2004001834A1 (es) 2003-07-23 2005-06-03 Bayer Pharmaceuticals Corp Compuesto 4-{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenoxi}-piridin-2-metilamida, inhibidor de la raf, vegfr, p38 y pdgfr quinasas, sus sales; composiicon farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperprol
EP2284157A1 (de) 2003-12-12 2011-02-16 Wyeth Quinolinen zur behandlung von cardiovascular krankheiten
WO2006010082A1 (en) * 2004-07-08 2006-01-26 Arqule, Inc. 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase
EP1809636A1 (de) * 2004-10-19 2007-07-25 Arqule, Inc. Synthese aus imidazooxazol- und imidazothiazol-hemmern der p38-map-kinase
US7479558B2 (en) * 2005-03-25 2009-01-20 Glaxo Group Limited Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives
PE20100737A1 (es) * 2005-03-25 2010-11-27 Glaxo Group Ltd Nuevos compuestos
ATE491023T1 (de) * 2005-06-10 2010-12-15 Univ Madrid Autonoma Neuer phosphorylierungsstandort für mitogenaktivierte proteinkinasen und modifizierte proteine sowie anwendungen davon
CN1995345B (zh) * 2006-08-31 2010-12-29 辽宁师范大学 重组日本七鳃鳗口腔腺分泌具抗炎功效l-251蛋白
EP2247558B1 (de) * 2008-02-14 2022-02-02 Eli Lilly and Company Neue bildgebungsmittel für den nachweis neurologischer dysfunktionen
US8932557B2 (en) 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
KR20110046503A (ko) * 2008-07-24 2011-05-04 지멘스 메디컬 솔루션즈 유에스에이, 인크. Ａｄ 병인을 확인하기에 유용한 영상화제
BRPI0921862A2 (pt) * 2008-12-05 2015-12-29 Arqule Inc inibidores de raf e seus usos
US8691187B2 (en) * 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
CA2756137C (en) * 2009-03-23 2015-11-24 Siemens Medical Solutions Usa, Inc. Imaging agents for detecting neurological disorders
ES2926931T3 (es) 2014-02-07 2022-10-31 Agency Science Tech & Res Inhibidores de caseína quinasa 1 basados en azoles 2,4,5-tri-sustituidos como inductores de la cardiomiogénesis
US10669528B2 (en) 2015-06-25 2020-06-02 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
EP3429603B1 (de) 2016-03-15 2021-12-29 Children's Medical Center Corporation Verfahren und zusammensetzungen im zusammenhang mit der expansion hämatopoetischer stammzellen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778806A (en) * 1986-08-19 1988-10-18 Smithkline Beckman Corporation Inhibition of interleukin-1 production by monocytes and/or macrophages
US4780470A (en) * 1986-08-19 1988-10-25 Smithkline Beckman Corporation Inhibition of interleukin-1 by monocytes and/or macrophages
US4794114A (en) * 1986-08-19 1988-12-27 Smithkline Beckman Corporation Inhibition of interleukin-1 production by monocytes and/or macrophages
JPH05503919A (ja) * 1989-06-13 1993-06-24 スミスクライン・ビーチャム・コーポレイション 単球および／またはマクロファージによるインターロイキン―１または腫瘍壊死因子生成の抑制
US5512473A (en) * 1993-01-29 1996-04-30 Brent; Roger Max-interacting proteins and related molecules and methods
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds

Also Published As

Publication number Publication date
CA2171982A1 (en) 1995-03-23
AU686669B2 (en) 1998-02-12
DE69421624T2 (de) 2000-07-20
EP0724588A4 (de) 1998-06-03
HK1012399A1 (en) 1999-07-30
US5871934A (en) 1999-02-16
WO1995007922A1 (en) 1995-03-23
US5777097A (en) 1998-07-07
GR3032635T3 (en) 2000-05-31
CN1134704A (zh) 1996-10-30
CA2171982C (en) 2000-02-01
NZ274063A (en) 1997-11-24
PT724588E (pt) 2000-05-31
ATE186551T1 (de) 1999-11-15
ES2140561T3 (es) 2000-03-01
CN1048731C (zh) 2000-01-26
US5955366A (en) 1999-09-21
JP3377529B2 (ja) 2003-02-17
EP0724588B1 (de) 1999-11-10
AU7798594A (en) 1995-04-03
EP0724588A1 (de) 1996-08-07
DK0724588T3 (da) 2000-05-15
JPH09502873A (ja) 1997-03-25

Similar Documents

Publication Publication Date Title
DE69421624T2 (de) Medikamente bindendes protein
EP0969093A3 (de) Protein, das Medikamente bindet
DE69940198D1 (de) Mikrovorrichtung zum screening von biomolekülen
GR880100198A (el) Τμήματα DNA, πολυπεπτίδια και αντισώματα σχετιζόμενα προς τον παράγοντα ιστών του αν?ρώπου.
CY1105895T1 (el) Χιμαιρικη πρωτεϊνη διαλυτου υποδοχεα/συνδετη ιντepλευκινης-6, αναλογα και αυτης και χρησεις αυτης
BR0009206A (pt) Isolamento e análise de proteina
CA2282497A1 (en) In vitro peptide or protein expression library
AU1208497A (en) Ligand polypeptides for the g-protein-coupled receptor protein, their production and use
DE69822307D1 (de) Menschliches adamts-1 protein, gen , welches für dieses kodiert, pharmazeutische zusammensetzung und verfahrem zur immunologischen bestimmung von menschlichen adamts-1 proteinen
ATE291585T1 (de) Traf-inhibitoren
HUP0002427A2 (hu) Leptin mint tumorsejt proliferációt gátló hatóanyag és alkalmazása
DE69531958D1 (de) (1-3)-beta-d-glukon-bindungsprotein, antikörper der dieses protein erkennt undverwendung des proteins und antikörper
ATE311443T1 (de) Methoden zur durchforstung (screenen) von proteinen
DE68925275T2 (de) Endotoxin-bindeprotein und dessen verwendung
AU7758598A (en) Stable pharmaceutical administration forms of peptides, proteins and nucleic acids
WO1999003993A3 (en) Suppressors of cytokine signaling; related reagents
BR9710919A (pt) Proteina purificada sr-p70
DK0707473T3 (da) Orale farmaceutiske præparater omfattende et protein eller et peptid, et antistof og polymerkugler
WO2002055669A3 (en) Regulation of target protein activity through modified proteins
DE3582812D1 (de) Dns-fragmente welche fuer peptide kodieren, die faehig sind in vivo die synthese von antihepatitis-a-virus-antikoerpern zu induzieren.
HUP9802289A2 (hu) Limfocita specifikus interferon szabályozó faktor (LSIRF) polipeptideket kódoló gének
NO993412L (no) Nye IFN-reseptor -1-bindende proteiner, DNA som koder for dem og metoder for modulering av cellulær respons for interferoner
BR1100801A (pt) Proteìna, peptìdeo, proteìna ou peptìdeo, sequência de dna, processo para a preparação de uma proteìna ou peptìdeo, anticorpo, composição farmacêutica, e, uso de uma proteìna ou peptìdeo

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: SMITHKLINE BEECHAM CORP., PHILADELPHIA, PA. 19103,

8364 No opposition during term of opposition